John H. Barton

Oncology

111 Hospital Dr
Tarboro, NC 27886

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3 publications

A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas.

A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas.

Journal: The oncologist

Published: October 21, 2016

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Journal: Cancer chemotherapy and pharmacology

Published: January 13, 2016

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.

Journal: Investigational new drugs

Published: September 04, 2014

Showing 1-3 of 3

Last Updated: 09/26/2026